Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.040
+0.010 (0.97%)
At close: Dec 18, 2025, 4:00 PM EST
1.040
0.00 (0.00%)
After-hours: Dec 18, 2025, 5:27 PM EST
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
17.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APVO News
- 9 days ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 5 weeks ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 6 weeks ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 3 months ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire
- 3 months ago - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Accesswire
- 4 months ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire